logo
Plus   Neg
Share
Email

CoreLogic Q4 Net Loss Narrows; Reconfirms FY12 Guidance - Quick Facts

CoreLogic, Inc. (CLGX) reported that its fourth-quarter net loss attributable to the company narrowed to $14.14 million or $0.13 per share, from $27.74 million or $0.24 per share in the same quarter last year.

Operating revenue for the quarter rose to $345.40 million from $315.37 million in the prior year quarter. Analysts polled by Thomson Reuters expected the company to report revenues of $330.68 million for the quarter. Analysts' estimates typically exclude special items.

The company reconfirmed its guidance for 2012. The company still expects adjusted earnings in a range of $0.95 to $1.05 and adjusted revenue of $1.425 billion to $1.475 billion for fiscal year 2012. Analysts expect the company to report earnings of $0.95 per share on revenues of $1.47 billion for fiscal 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT